- Home
- ONEG vs CMMB Comparison
ONEG vs CMMB Comparison
Compare ONEG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONEG
- CMMB
- Stock Information
- Founded
- ONEG 2021
- CMMB 2004
- Country
- ONEG Hong Kong
- CMMB Israel
- Employees
- ONEG N/A
- CMMB N/A
- Industry
- ONEG Homebuilding
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ONEG Consumer Discretionary
- CMMB Health Care
- Exchange
- ONEG Nasdaq
- CMMB Nasdaq
- Market Cap
- ONEG 27.3M
- CMMB 23.6M
- IPO Year
- ONEG 2024
- CMMB N/A
- Fundamental
- Price
- ONEG $3.30
- CMMB $1.26
- Analyst Decision
- ONEG
- CMMB Strong Buy
- Analyst Count
- ONEG 0
- CMMB 2
- Target Price
- ONEG N/A
- CMMB $9.00
- AVG Volume (30 Days)
- ONEG 46.8K
- CMMB 92.1K
- Earning Date
- ONEG 01-01-0001
- CMMB 05-20-2025
- Dividend Yield
- ONEG N/A
- CMMB N/A
- EPS Growth
- ONEG N/A
- CMMB N/A
- EPS
- ONEG 0.12
- CMMB N/A
- Revenue
- ONEG $60,903,000.00
- CMMB N/A
- Revenue This Year
- ONEG N/A
- CMMB N/A
- Revenue Next Year
- ONEG N/A
- CMMB N/A
- P/E Ratio
- ONEG $26.44
- CMMB N/A
- Revenue Growth
- ONEG 16.46
- CMMB N/A
- 52 Week Low
- ONEG $1.48
- CMMB $0.60
- 52 Week High
- ONEG $4.05
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ONEG N/A
- CMMB 50.43
- Support Level
- ONEG N/A
- CMMB $1.15
- Resistance Level
- ONEG N/A
- CMMB $1.45
- Average True Range (ATR)
- ONEG 0.00
- CMMB 0.09
- MACD
- ONEG 0.00
- CMMB 0.00
- Stochastic Oscillator
- ONEG 0.00
- CMMB 45.71
About ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. It is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project include performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.